1 results match your criteria: "Hematologic Malignancies. H. Lee Moffitt Cancer Center and Research Institute[Affiliation]"
Article Synopsis
- - The drug development for chronic myelomonocytic leukemia (CMML) has lagged behind successes in other related blood diseases, prompting concern among experts.
- - In September 2023, the FDA organized a symposium to address CMML, bringing together regulators and researchers to identify challenges and discuss future strategies for drug development.
- - The discussions focused on issues like clinical trial design, study endpoints, and regulatory considerations to improve therapeutic options for CMML.